ZBIO Maintain Outperform and $45 PT ahead of AMGN earnings as reiterate Wedbush's case for a valuation of $2.4B ($26/sh) for ZBIO's obexelim

ZBIO Maintain Outperform and $45 PT ahead of AMGN earnings as reiterate Wedbush's case for a valuation of $2.4B ($26/sh) for ZBIO's obexelimab in IgG4-RD alone @ Wedbush